-
Most Recent
Biotech Stocks
Biotech is defined as using technology to change, manipulate, and harness biological processes in order to fulfill a medical need. The applications of biotech are endless and range from genetically modifying foods to creating vaccines. During the height of the coronavirus pandemic, companies like Moderna and BioNTech utilized biotech to create life-saving vaccines that were distributed across the globe.
7 Recession-Resistant Stocks to Hold Onto for Dear Life in 2024
These seven recession-resistant stocks offer stability and potential growth even in challenging economic conditions.
3 Promising Biotech Stocks for the Long-Term: August 2024
Some of the best biotech opportunities can be found in oversold obesity treatment stocks. Here are just a few.
The 3 Best Healthcare Stocks to Buy in August 2024
These are the best healthcare stocks that could bring in massive returns to the investors in the future. Do not miss out on this opportunity.
Other industries you might be interested in
Recent Biotech Stocks Articles
Investors Still Must Pick Generic Drug Companies By Hand
The high-risk generic drug sector still is without an ETF, leaving investors to weed out the pharmaceutical winners and losers for themselves.
Biogen Is in the Right Place at the Right Time
BIIB's promising multiple scerlosis drug BG-12 could be a huge winner, just when Novartis' entry is stumbling.
Onyx Pharma May See Suitors Lining Up
The company's current and future drugs are likely attractive to larger companies faced with slowing growth.
Ranbaxy Closes In on FDA Approval for Generic Lipitor
Ranbaxy could sell $650 million worth of the drug in its first 180 days. But Pfizer is battling hard to keep branded Lipitor alive.
Forget Amgen — Buy This Pharmaceutical Stock Instead
Amgen is a world-class biotech company, but its big growth is a thing of the past. Another pharma stock is positioning itself for a place in your portfolio.
Blood-Thinner Drug Race Is Still Wide Open
The major pharmaceutical companies are hoping to supply the definitive treatments, but the medical community hasn't yet declared a winner.
Merck CEO Pledges Drug Pipeline Will Yield Results in Both Short and Long Term
Merck CEO Kenneth Frazier acknowledges company's lagging stock, touts potential of numerous drugs in late development stages.
Pfizer’s Latest Gambit for Keeping Lipitor Alive
Like a vampire refusing to die, Lipitor keeps on going. Now, PFE has a deal to sell the cholesterol-lowering drug directly to patients at generic cost.
Gilead’s Giant Gamble in Buying Pharmasset
The $11B price tag raises the stakes big-time, and critics say Gilead is overpaying to get Pharmasset's promising hepatitis C treatment.
Bank on This Pair of Biotech Bargains
When it comes to small biotechs, one successful product can send its stock soaring. This pair of companies currently have promising treatments on the horizon.
Stocks to Watch on Cancer Vaccines’ Huge Financial Potential
These companies are making progress on new therapeutic cancer vaccines -- and success for any one of them could be huge for investors.
Big Pharma’s Emerging Markets Foray Hits Roadblocks
Companies are finding plans for global expansion aren't without hiccups.
Bristol-Myers, AstraZeneca Diabetes Drug Gets New Hope
Cleveland Clinic's positive review revitalizes Bristol-Myers, AstraZeneca's dapagliflozin, an experimental drug taking on a growing diabetes management market.
Sanofi Relies on Shopping to Offset Patent Losses on Key Drugs
French drug giant Sanofi (SNY) is counting on mergers and acquisitions to restore profit growth amid a slew of patent expirations.
Pfizer Pushes to Keep Lipitor Profits Flowing
Efforts to preserve the lucrative cholesterol-drug's franchise have sparked an antitrust suit. But competition is inevitable.
10 Companies Increasing Dividends
Merck and ADP top the list of stocks increasing dividends this week. See eight other companies making shareholders smile.
Amylin Stumbles After Lilly Pulls Partnership Plug
As Eli Lilly looks elsewhere for a diabetes drug partner, Amylin Pharmaceuticals stumbles. But Lilly is happy as can be. Here's why.
Hepatitis C Drug Progress Puts Several Companies on Acquisition Watch
With their hepatitis C drugs showing promise in trials, these drug makers have become attractive targets for bigger pharma players.
